Position in XGN
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$759,015
+$548,976 QoQ
Shares Held
253,005
+632.4% QoQ
Ownership
1.05%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in XGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026GSA CAPITAL PARTNERS LLP holds $12,036,211 across 17 Diagnostics & Research names. XGN ranks #5 (6.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DHR |
Danaher Corp /De/
|
13,542 | $2,567,563 | |
| 2 | IDXX |
Idexx Laboratories Inc /De
|
2,801 | $1,573,853 | |
| 3 | MYGN |
Myriad Genetics Inc
|
339,902 | $1,529,559 | |
| 4 | A |
Agilent Technologies, Inc.
|
8,721 | $994,019 | |
| 5 | XGN |
Exagen Inc.
This page
|
253,005 | $759,015 | |
| 6 | OPK |
Opko Health, Inc.
|
663,704 | $756,622 | |
| 7 | BDSX |
Biodesix Inc
|
39,406 | $571,387 | |
| 8 | PSNL |
Personalis, Inc.
|
82,175 | $523,454 |
All Filings in XGN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $759,015 | 253,005 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $210,039 | 34,546 | Shares | Sole | 2026-02-06 | |
| 2025-03-31 | $44,110 | 12,287 | Shares | Sole | 2025-05-08 | |
| No filing history on record for this holder in this stock. | ||||||